Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn

Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.